Literature DB >> 17387265

Inhibition of lipoxygenase activity: implications for the treatment and chemoprevention of prostate cancer.

Mark A Nelson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17387265     DOI： 10.4161/cbt.6.2.4120

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


× No keyword cloud information.
  1 in total

1.  Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.

Authors:  Ajaikumar B Kunnumakkara; Bokyung Sung; Jayaraj Ravindran; Parmeswaran Diagaradjane; Amit Deorukhkar; Sanjit Dey; Cemile Koca; Zhimin Tong; Juri G Gelovani; Sushovan Guha; Sunil Krishnan; Bharat B Aggarwal
Journal:  Int J Cancer       Date:  2011-11-09       Impact factor: 7.396
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.